Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aviva Systems Biology Corp.

www.avivasysbio.com

Latest From Aviva Systems Biology Corp.

Deals Shaping The Medical Industry, March 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2017.

Deals BioPharmaceutical

Lectus Therapeutics Ltd.

Lectus was founded in December 2002, to develop and commercialize a second generation of ion channel modulating drugs. By targeting the plethora of accessory proteins that regulate the activity of the ion channel pore-forming proteins rather than the pore-forming proteins themselves Lectus believes its drugs will be safer and more effective than currently marketed products.
BioPharmaceutical Business Strategies

Enabling a Comeback in Ion Channel Drug Discovery

Automated medium- and high-throughput ion channel screening systems promise to jump start the search for ion channel modulating drugs, a vast and promising area of drug discovery. In Vivo Europe Rx looks at Sophion Bioscience, Nanion Technologies, and Xention Discovery, three emerging European firms whose platforms may help return ion channels to the forefront of biotech and pharmaceutical companies' discovery targets.
BioPharmaceutical Europe

The Re-Emergence of Ion Channel Drug Discovery

Historically ion channels have been among the most attractive targets for therapeutic intervention. But discovery of new ion channel drugs has come to a halt because ion channels are difficult to assay, require specialized tools and skills to study adequately, and have historically been impossible to study directly in high-throughput mode-the preferred style of the last decade. Now, a variety of automated assay technologies are coming on the market that should increase throughput, and some drug discovery companies have developed proprietary high-throughput methods for in-house use. With industry now interested more than ever in applying higher-throughput technologies to precedented targets, in a sense, ion channel discovery may become a beneficiary of the failures of genomics, combinatorial chemistry, and high-throughput screening.
BioPharmaceutical Platform Technologies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
    • Large Molecule
      • Antibodies
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Aviva Biosciences Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Aviva Systems Biology Corp.
  • Senior Management
  • Peter Jiang, MD, Pres. & CEO
    Matt Landry, VP, Mktg. & Sales
    Joseph Wong, Dir., Operations
  • Contact Info
  • Aviva Systems Biology Corp.
    Phone: (858) 552-6979
    5754 Pacific Center Blvd
    Ste. 201
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register